Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olpasiran in Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
NCT05581303Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2022
- Primary completion
- Mar 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) comparing Placebo with Olpasiran (2 arms). Primary endpoint: Time to CHD death, myocardial infarction, or urgent coronary revascularization at 5 years. Started Dec 2022; status: active, not recruiting.
02
Drugs
olpasiran
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05581303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581303.